Placebo News and Research

RSS

New way of fortifying flour with iron helps combat anaemia

Researchers from Wageningen University, Unilever and Akzo Nobel will be making this known in the authoritative scientific journal, The Lancet, this week.

28 May 2007

FDA approves treatment for bacterial vaginosis

Mission Pharmacal has announced that the U.S. Food and Drug Administration (FDA) approved Tindamax (tinidazole) for the treatment of bacterial vaginosis (BV), the most common vaginal infection among women of childbearing age in the United States.

28 May 2007

Time to fortify the world's processed cereals

Fortifying cereals with a different type of iron supplement reduces anaemia, iron-deficiency anaemia and general iron deficiency children in developing countries, and boosts three major iron status indicators, conclude authors of an Article published in this week’s edition of The Lancet.

28 May 2007

Study of Aripiprazole in adolescents with schizophrenia

In a six-week study in adolescents (13-17 years old) with schizophrenia, the Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company atypical antipsychotic aripiprazole demonstrated significant improvement compared to placebo on the primary efficacy endpoint, Positive and Negative Syndrome Scale (PANSS) Total Score.

24 May 2007

Clinical study results on bifeprunox for schizophrenia

Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals and Lundbeck A/S presented clinical study results on bifeprunox, an investigational treatment for adult patients diagnosed with schizophrenia, at the 2007 annual meeting of the American Psychiatric Association.

24 May 2007

Long-term ulcerative colitis study shows Remicade responders maintained improvement

Findings presented at Digestive Disease Week 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects with moderately to severely active ulcerative colitis (UC) who had responded to REMICADE (infliximab) in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.

24 May 2007

Daytrana provides significant effectiveness in both boys and girls with ADHD

Shire plc has announced that DAYTRANA (methylphenidate transdermal system), its Attention Deficit Hyperactivity Disorder (ADHD) patch, had significant efficacy in reducing the symptoms of ADHD in both male and female children aged 6 to 12 years, according to clinical trial results reported at the American Psychiatric Association (APA) annual meeting in San Diego.

24 May 2007

Ramelteon does not impair balance, mobility or memory performance in older adults with insomnia

A new study presented today showed that ramelteon did not impair middle-of-the-night balance, mobility or memory performance in older adults with insomnia, relative to placebo.

24 May 2007

Iloperidone shows promise for Akathisia

According to study results presented at the 2007 American Psychiatric Association annual meeting, iloperidone, an investigational atypical antipsychotic, was shown to have a favorable akathisia profile.

24 May 2007

Efficacy and safety of Aripiprazole as adjunctive therapy in major depressive disorder

In adults with major depressive disorder, adding aripiprazole to antidepressant therapy (ADT) resulted in significant improvement in the primary endpoint, the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score.

24 May 2007

SYMBICORT trial shows improved quality of life with asthma

New data demonstrated that the combination asthma therapy, SYMBICORT (budesonide/formoterol fumarate dihydrate), led to significant improvements in health-related quality of life (HRQL) and greater patient-reported satisfaction with asthma treatment, versus its monocomponents (budesonide or formoterol) or placebo.

24 May 2007

Lubiprostone may improve symptom relief rates in adults with irritable bowel syndrome with constipation

A new study demonstrated that the active ingredient in AMITIZA (lubiprostone), given 8 mcg twice a day, may improve symptom relief rates in adults with irritable bowel syndrome with constipation (IBS-C).

22 May 2007

Lubiprostone may improve symptom relief rates in adults with irritable bowel syndrome

22 May 2007

GSK strongly disagrees with conclusions reached in NEJM article on Avandia

GlaxoSmithKline has issued the following response to an article in the New England Journal of Medicine (NEJM) on Avandia (rosiglitazone maleate), a widely used and highly effective treatment for type 2 diabetes.

22 May 2007

Drug treatment slows decline in lung function in COPD patients

Treatment with a commonly used drug slows the decline in lung function in patients with chronic obstructive pulmonary disease (COPD), according to results from the TORCH (TOwards a Revolution in COPD Health) study presented at the American Thoracic Society 2007 International Conference, on Tuesday, May 22.

22 May 2007

CoQ10 may not provide benefits to individuals with Parkinson's disease

These findings contradict results from earlier studies involving a high purity CoQ10 supplement, Vitaline(R) CoQ10. Richard M. Delany, M.D., FACC, and founder of Personalized Preventive Medicine, finds that a closer review of this latest study design reveals important weaknesses, including the use of a short study duration (3 months) and a low daily dosage (300 mg), and failure to use the clinically proven CoQ10 product, Vitaline CoQ10.

22 May 2007

Clinical trial data for Perforomist Inhalation solution

Data presented at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist (formoterol fumarate) Inhalation Solution, delivered by nebulization, is an effective and well-tolerated new treatment option for patients suffering from emphysema or chronic bronchitis, otherwise known as Chronic Obstructive Pulmonary Disease (COPD).

22 May 2007

Danube Pharmaceuticals starts trial of DNB-001 in patients with ocular hypertension

Danube Pharmaceuticals, Inc. has announced the initiation of a multi-center, randomized, double-blind, placebo controlled Phase II study with DNB-001 in 60 patients with ocular hypertension (elevated intraocular pressure).

18 May 2007

ACE inhibitors help preserve kidney function in IgA nephropathy

For young patients with the kidney disease IgA nephropathy (IgAN), early treatment with angiotensin-converting enzyme (ACE) inhibitors can reduce the long-term risk of irreversible kidney damage, suggests a study in the June Journal of the American Society of Nephrology.

17 May 2007

Single dose of vitamin D may be enough to boost the immune system to fight against tuberculosis

Their findings came from a study that identified an extraordinarily high incidence of vitamin D deficiency amongst those communities in London most at risk from the disease, which kills around two million people each year.

16 May 2007